17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenstral women

P. S. Jhund, N. Dawson, A. P. Davie, John David Norrie, K. P. J. O'Kane, J. J. V. McMurray

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Purpose: It is thought that oestrogen replacement therapy may reduce the conversion of angiotensin I to angiotensin II in postmenopausal women by inhibiting angiotensin converting enzyme. We sought to determine the effects of 3 months oestrogen replacement therapy (ERT) on the response to angiotensin I and II in postmenopausal women.

    Methods: Eighteen postmenopausal women were randomised to either three months of 2 mg oral oestradiol or placebo in a double blind, placebo controlled, protocol. Change in forearm blood flow (FBF), in response to brachial arterial infusion of increasing concentrations of angiotensin I and angiotensin II was measured, pre-randomisation, after 1 months randomised therapy and after 3 months therapy, using venous occlusion plethysmography.

    Results: Oestrogen treatment had no effect on baseline FBF. The mean (SD) peak reductions in FBF with 64 pmol/min angiotensin I pre-randomisation, after 1 month and after 3 months treatment with placebo were 62(11), 65(15) and 57(8)%. The corresponding reductions with the peak dose of angiotensin II (16 pmol/min) were 53(8), 48( 12) and 47(11)%. In the oestradiol group, the peak responses to angiotensin I were 56( 8), 53( 11) and 44( 29)% pre-randomisation, after 1 months treatment and after 3 months treatment. The corresponding reductions in response to angiotensin II were 37( 15), 47( 15) and 45( 19)%. Oestradiol did not affect the response to either angiotensin I or angiotensin II.

    Conclusion: This study does not support the idea that ERT might exert a cardioprotective effect through inhibition of the renin-angiotensin system.

    Original languageEnglish
    Pages (from-to)31-36
    Number of pages5
    JournalCardiovascular Drugs and Therapy
    Volume18
    Issue number1
    DOIs
    Publication statusPublished - 2004

    Keywords

    • arteries
    • angiotensin I
    • angiotensin II
    • hormones
    • women
    • CORONARY-HEART-DISEASE
    • ESTROGEN REPLACEMENT THERAPY
    • INDUCED VASOCONSTRICTION
    • PLUS PROGESTIN
    • HEALTH
    • TRIAL
    • NOREPINEPHRINE
    • ARTERIES
    • FAILURE
    • RISK

    Cite this

    17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenstral women. / Jhund, P. S.; Dawson, N.; Davie, A. P.; Norrie, John David; O'Kane, K. P. J.; McMurray, J. J. V.

    In: Cardiovascular Drugs and Therapy, Vol. 18, No. 1, 2004, p. 31-36.

    Research output: Contribution to journalArticle

    Jhund, P. S. ; Dawson, N. ; Davie, A. P. ; Norrie, John David ; O'Kane, K. P. J. ; McMurray, J. J. V. / 17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenstral women. In: Cardiovascular Drugs and Therapy. 2004 ; Vol. 18, No. 1. pp. 31-36.
    @article{a140536eb1e64716b37fc05348dfcdec,
    title = "17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenstral women",
    abstract = "Purpose: It is thought that oestrogen replacement therapy may reduce the conversion of angiotensin I to angiotensin II in postmenopausal women by inhibiting angiotensin converting enzyme. We sought to determine the effects of 3 months oestrogen replacement therapy (ERT) on the response to angiotensin I and II in postmenopausal women.Methods: Eighteen postmenopausal women were randomised to either three months of 2 mg oral oestradiol or placebo in a double blind, placebo controlled, protocol. Change in forearm blood flow (FBF), in response to brachial arterial infusion of increasing concentrations of angiotensin I and angiotensin II was measured, pre-randomisation, after 1 months randomised therapy and after 3 months therapy, using venous occlusion plethysmography.Results: Oestrogen treatment had no effect on baseline FBF. The mean (SD) peak reductions in FBF with 64 pmol/min angiotensin I pre-randomisation, after 1 month and after 3 months treatment with placebo were 62(11), 65(15) and 57(8){\%}. The corresponding reductions with the peak dose of angiotensin II (16 pmol/min) were 53(8), 48( 12) and 47(11){\%}. In the oestradiol group, the peak responses to angiotensin I were 56( 8), 53( 11) and 44( 29){\%} pre-randomisation, after 1 months treatment and after 3 months treatment. The corresponding reductions in response to angiotensin II were 37( 15), 47( 15) and 45( 19){\%}. Oestradiol did not affect the response to either angiotensin I or angiotensin II.Conclusion: This study does not support the idea that ERT might exert a cardioprotective effect through inhibition of the renin-angiotensin system.",
    keywords = "arteries, angiotensin I, angiotensin II, hormones, women, CORONARY-HEART-DISEASE, ESTROGEN REPLACEMENT THERAPY, INDUCED VASOCONSTRICTION, PLUS PROGESTIN, HEALTH, TRIAL, NOREPINEPHRINE, ARTERIES, FAILURE, RISK",
    author = "Jhund, {P. S.} and N. Dawson and Davie, {A. P.} and Norrie, {John David} and O'Kane, {K. P. J.} and McMurray, {J. J. V.}",
    year = "2004",
    doi = "10.1023/B:CARD.0000025753.20686.2b",
    language = "English",
    volume = "18",
    pages = "31--36",
    journal = "Cardiovascular Drugs and Therapy",
    issn = "0920-3206",
    publisher = "Kluwer Academic Publishers",
    number = "1",

    }

    TY - JOUR

    T1 - 17 beta oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenstral women

    AU - Jhund, P. S.

    AU - Dawson, N.

    AU - Davie, A. P.

    AU - Norrie, John David

    AU - O'Kane, K. P. J.

    AU - McMurray, J. J. V.

    PY - 2004

    Y1 - 2004

    N2 - Purpose: It is thought that oestrogen replacement therapy may reduce the conversion of angiotensin I to angiotensin II in postmenopausal women by inhibiting angiotensin converting enzyme. We sought to determine the effects of 3 months oestrogen replacement therapy (ERT) on the response to angiotensin I and II in postmenopausal women.Methods: Eighteen postmenopausal women were randomised to either three months of 2 mg oral oestradiol or placebo in a double blind, placebo controlled, protocol. Change in forearm blood flow (FBF), in response to brachial arterial infusion of increasing concentrations of angiotensin I and angiotensin II was measured, pre-randomisation, after 1 months randomised therapy and after 3 months therapy, using venous occlusion plethysmography.Results: Oestrogen treatment had no effect on baseline FBF. The mean (SD) peak reductions in FBF with 64 pmol/min angiotensin I pre-randomisation, after 1 month and after 3 months treatment with placebo were 62(11), 65(15) and 57(8)%. The corresponding reductions with the peak dose of angiotensin II (16 pmol/min) were 53(8), 48( 12) and 47(11)%. In the oestradiol group, the peak responses to angiotensin I were 56( 8), 53( 11) and 44( 29)% pre-randomisation, after 1 months treatment and after 3 months treatment. The corresponding reductions in response to angiotensin II were 37( 15), 47( 15) and 45( 19)%. Oestradiol did not affect the response to either angiotensin I or angiotensin II.Conclusion: This study does not support the idea that ERT might exert a cardioprotective effect through inhibition of the renin-angiotensin system.

    AB - Purpose: It is thought that oestrogen replacement therapy may reduce the conversion of angiotensin I to angiotensin II in postmenopausal women by inhibiting angiotensin converting enzyme. We sought to determine the effects of 3 months oestrogen replacement therapy (ERT) on the response to angiotensin I and II in postmenopausal women.Methods: Eighteen postmenopausal women were randomised to either three months of 2 mg oral oestradiol or placebo in a double blind, placebo controlled, protocol. Change in forearm blood flow (FBF), in response to brachial arterial infusion of increasing concentrations of angiotensin I and angiotensin II was measured, pre-randomisation, after 1 months randomised therapy and after 3 months therapy, using venous occlusion plethysmography.Results: Oestrogen treatment had no effect on baseline FBF. The mean (SD) peak reductions in FBF with 64 pmol/min angiotensin I pre-randomisation, after 1 month and after 3 months treatment with placebo were 62(11), 65(15) and 57(8)%. The corresponding reductions with the peak dose of angiotensin II (16 pmol/min) were 53(8), 48( 12) and 47(11)%. In the oestradiol group, the peak responses to angiotensin I were 56( 8), 53( 11) and 44( 29)% pre-randomisation, after 1 months treatment and after 3 months treatment. The corresponding reductions in response to angiotensin II were 37( 15), 47( 15) and 45( 19)%. Oestradiol did not affect the response to either angiotensin I or angiotensin II.Conclusion: This study does not support the idea that ERT might exert a cardioprotective effect through inhibition of the renin-angiotensin system.

    KW - arteries

    KW - angiotensin I

    KW - angiotensin II

    KW - hormones

    KW - women

    KW - CORONARY-HEART-DISEASE

    KW - ESTROGEN REPLACEMENT THERAPY

    KW - INDUCED VASOCONSTRICTION

    KW - PLUS PROGESTIN

    KW - HEALTH

    KW - TRIAL

    KW - NOREPINEPHRINE

    KW - ARTERIES

    KW - FAILURE

    KW - RISK

    U2 - 10.1023/B:CARD.0000025753.20686.2b

    DO - 10.1023/B:CARD.0000025753.20686.2b

    M3 - Article

    VL - 18

    SP - 31

    EP - 36

    JO - Cardiovascular Drugs and Therapy

    JF - Cardiovascular Drugs and Therapy

    SN - 0920-3206

    IS - 1

    ER -